{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:48:08Z","timestamp":1785854888162,"version":"3.56.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.1097\/qai.0b013e31824f5506","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T06:40:12Z","timestamp":1329979212000},"page":"117-123","source":"Crossref","is-referenced-by-count":11,"title":["Differences in Virological Response to Peginterferon-\u03b1 Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b"],"prefix":"10.1097","volume":"60","author":[{"given":"Norma I.","family":"Rall\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Neukam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Vispo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Labarga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Caruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210131","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection.","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-2-20210131","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":". Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"R3-2-20210131","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":". and American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R4-2-20210131","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C.","volume":"49","author":"Kau","year":"2008","journal-title":"J Hepatol"},{"key":"R5-2-20210131","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":". Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R6-2-20210131","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":". IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"R7-2-20210131","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":". Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"R8-2-20210131","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":". Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIVhepatitis C virus-coinfected patients.","volume":"24","author":"Rallon","year":"2010","journal-title":"AIDS"},{"key":"R9-2-20210131","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":". Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"R10-2-20210131","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cgh.2010.07.019","article-title":". Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C.","volume":"9","author":"Stattermayer","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R11-2-20210131","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/QAD.0b013e3283471cae","article-title":". IL28B gene polymorphisms and viral kinetics in HIVHCV coinfected patients treated with pegylated interferon plus ribavirin.","volume":"25","author":"Rallon","year":"2011","journal-title":"AIDS"},{"key":"R12-2-20210131","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","article-title":"New therapies for hepatitis C virus infection.","volume":"48","author":"Soriano","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R13-2-20210131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrgastro.2011.49","article-title":"A new standard of care for the treatment of chronic HCV infection.","volume":"8","author":"Hofmann","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R14-2-20210131","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":". Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordard","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-2-20210131","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":". Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"R16-2-20210131","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct acting antiviral agents in patients with hepatitis C virus infection.","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"R17-2-20210131","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/jac\/dkq284","article-title":"Hepatitis C virus directly acting antivirals: current developments with NS34A HCV serine protease inhibitors.","volume":"65","author":"Naggie","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R18-2-20210131","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/656235","article-title":". Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.","volume":"51","author":"Pineda","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R19-2-20210131","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/630205","article-title":". Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.","volume":"49","author":"Medrano","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R20-2-20210131","doi-asserted-by":"crossref","first-page":"e8209","DOI":"10.1371\/journal.pone.0008209","article-title":". Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.","volume":"4","author":"Chevaliez","year":"2009","journal-title":"PLoS One"},{"key":"R21-2-20210131","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":". Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"R22-2-20210131","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/597350","article-title":". Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.","volume":"48","author":"Kirk","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R23-2-20210131","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jac\/dkr488","article-title":". Association between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in Brazil.","volume":"67","author":"Ferreira","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R24-2-20210131","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiq098","article-title":". Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.","volume":"203","author":"Natterman","year":"2011","journal-title":"J Infect Dis"},{"key":"R25-2-20210131","doi-asserted-by":"crossref","first-page":"e13771","DOI":"10.1371\/journal.pone.0013771","article-title":". IL28B SNP rs8099917 is strongly associated with pegylated interferon- and ribavirin therapy treatment failure in HCVHIV-1 coinfected patients.","volume":"5","author":"Aparicio","year":"2010","journal-title":"PLoS One"},{"key":"R26-2-20210131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/QAI.0b013e3182020596","article-title":". Pharmacodynamics of PEG-IFN-2a and HCV response as a function of IL28B polymorphism in HIVHCV-coinfected patients.","volume":"56","author":"de Araujo","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R27-2-20210131","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkr439","article-title":". Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIVHCV co-infected patients with genotype 1 or 4.","volume":"67","author":"Rivero-Juarez","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R28-2-20210131","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":". Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon -2a (40Kd)ribavirin therapy.","volume":"43","author":"Jensen","year":"2006","journal-title":"Hepatology"},{"issue":"suppl 1","key":"R29-2-20210131","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0168-8278(11)60065-2","article-title":". Characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052.","volume":"54","author":"McPhee","year":"2011","journal-title":"J Hepatol"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201206010-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:51:50Z","timestamp":1785851510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201206010-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31824f5506","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}